Company is financial health with $18m dollars in cash and growing revenues. Last year they made a loss of $22m, but with a cut in yearly costs of $6m and with dignificantly growing revenues, an FDA approval in the very near term and an estimate of breakeven cash flow they won't be needing financing.
News 
Market Data 
Discover 
